Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients

Thrombosis Research

Volumn 120, Issue 6, 2007, Pages 797-803

  Pawlak, Krystyna ^a   Pawlak, Dariusz ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Coagulation; Endothelium; Erythropoietin (rHuEPO); Haemodialysis; Oxidative stress

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PROTHROMBIN; RECOMBINANT ERYTHROPOIETIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HEMODIALYSIS; HUMAN; LONG TERM CARE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT DURATION; UREMIA;

ADULT; AGED; ANEMIA; BIOLOGICAL MARKERS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TIME FACTORS; UREMIA;

EID: 34548663552     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.02.004     Document Type: Article

References (29)

1. Yao Q., Pecoits-Filho R., Lindholm B., and Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 38 (2004) 405-416
2. Małyszko J., Małyszko J.S., Pawlak D., Pawlak K., Buczko W., and Myśliwiec M. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 83 (1996) 351-361
3. Małyszko J.S., Małyszko J., Pawlak K., Pawlak K., Buczko W., and Myśliwiec M. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin. Nephron 84 (2000) 305-311
4. Mezzano D., Pais E.O., Aranda E., Panes O., Downey P., Ortiz M., et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60 (2001) 1844-1850
5. Borawski J., and Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost 8 (2002) 77-84
6. Staško J., and Kubisz P. Increased soluble thrombomodulin in hemodialysis patients with long-term erythropoietin treatment: what does it reflect?. Clin Appl Thromb Hemost 9 (2003) 349-352
7. Naumnik B., Borawski J., and Myśliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. Nephrol Dial Transplant 18 (2003) 1376-1382
8. Małyszko J., Małyszko J.S., and Myśliwiec M. Tissue factor and tissue factor inhibitor in acute and chronic renal failure. Thromb Haemost 80 (1998) 722-724
9. Boaz M., Green M., Fainauru M., and Smetana S. Oxidative stress and cardiovascular disease in hemodialysis. Clin Nephrol 55 (2001) 93-100
10. Himmelfarb J., Stenvinkel P., Ikizler T.A., and Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
11. Taylor J.E., Belch J.J.F., McLaren M., Henderson J.S., and Stewart W.K. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 44 (1993) 182-190
12. Christensson A.G., Danielson B.G., and Lethagen S.R. Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis. Nephrol Dial Transplant 16 (2001) 313-319
13. Borawski J., Naumnik B., and Mysliwiec M. Short-term erythropoietin therapy does not increase plasma tissue factor and its inhibitor levels in hemodialysis patients. Clin Appl Thromb Hemost 9 (2003) 173-174
14. Ambuhl P.M., Wuthrich R.P., Korte W., Schmid L., and Krapf R. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial Transplant 12 (1997) 2355-2364
15. Kuriyama S., Hopp L., Yoshida H., Hikita M., Tomonari H., Hashimoto T., et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 9 (1996) 426-431
16. Mircescu G., Cǎapusǎ C., Stoian I., Mǎrǎcine M., Mascurel C., Gârneatǎ L., et al. Influence of epoietinum therapy on the oxidative stress in haemodialysis patients. Nephron Clin Pract 100 (2005) c126-c132
17. Usberti M., Gerardi G., Bufano G., Tira P., Micheli A., Albertini A., et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. Am J Kidney Dis 40 (2002) 590-599
18. Herrera J., Nava M., Romero F., and Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37 (2001) 750-757
19. Pawlak K., Naumnik B., Brzósko S., Pawlak D., and Myśliwiec M. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol 24 (2004) 154-161
20. Canaud B., Cristol J.P., Morena M., Leray-Moragues H., Bose J.Y., and Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 17 (1999) 99-106
21. Sommerburg O., Grune T., Hampl H., Riedel E., van Kuijk F.J., Ehrich J.H., et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in hemodialysed patients?. Nephrol Dial Transplant 13 (1998) 2583-2587
22. Bonomini M., Sirolli V., Merciaro G., Antidormi T., Di Liberato L., Brummer U., et al. Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine. Nephrol Dial Transplant 20 (2005) 361-366
23. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3527-3561
24. Malyszko J., Malyszko J.S., Hryszko T., Pawlak K., and Mysliwiec M. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients. Am J Nephrol 24 (2004) 624-629
25. Koenig W., and Ernst E. Fibrinogen and atherothrombosis. Curr Opin Lipidol 4 (1993) 471-476
26. Irish A. Cardiovascular disease, fibrinogen and the acute phase response associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 137 (1998) 133-139
27. Pawlak K., Pawlak D., and Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 38 (2005) 700-705
28. Lim P.-S., Wei Y.-H., Yu Y.L., and Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14 (1999) 2680-2687
29. Roob J.M., Khoschsorur G., Tiran A., Horina J.H., Holzer H., and Winklhofer-Roob B.M. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11 (2000) 539-549